MYRIAD GENETICS INC
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 28, 2025.
| MYRIAD GENETICS, INC. | |
| By: | /s/ Paul J. Diaz |
|---|---|
| Paul J. Diaz | |
| President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.
| Signatures | Title | Date | |||
|---|---|---|---|---|---|
| President, Chief Executive Officer and Director (Principal Executive Officer) | |||||
| By: | /s/ Paul J. Diaz | February 28, 2025 | |||
| Paul J. Diaz | |||||
| Chief Financial Officer (Principal Financial Officer) | |||||
| By: | /s/ Scott J. Leffler | February 28, 2025 | |||
| Scott J. Leffler | |||||
| Chief Accounting Officer (Principal Accounting Officer) | |||||
| By: | /s/ Natalie Munk | February 28, 2025 | |||
| Natalie Munk | |||||
| By: | /s/ S. Louise Phanstiel | Chair of the Board | February 28, 2025 | ||
| S. Louise Phanstiel | |||||
| By: | /s/ Paul Bisaro | Director | February 28, 2025 | ||
| Paul Bisaro | |||||
| By: | /s/ Heiner Dreismann | Director | February 28, 2025 | ||
| Heiner Dreismann, Ph.D. | |||||
| By: | /s/ Rashmi Kumar | Director | February 28, 2025 | ||
| Rashmi Kumar | |||||
| By: | /s/ Lee N. Newcomer | Director | February 28, 2025 | ||
| Lee N. Newcomer, M.D. | |||||
| By: | /s/ Colleen F. Reitan | Director | February 28, 2025 | ||
| Colleen F. Reitan | |||||
| By: | /s/ Daniel M. Skovronsky | Director | February 28, 2025 | ||
| Daniel M. Skovronsky, M.D., Ph.D. | |||||
| By: | /s/ Mark S. Davis | Director | February 28, 2025 | ||
| Mark S. Davis | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.